The American Journal of Surgery
Volume 198, Issue 1 , Pages 46-50, July 2009

Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy

  • Marieke E. Straver, M.D.

      Affiliations

    • Department of Surgery, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +0031-20-5122999; fax: +0031-20-5122554
  • ,
  • Emiel J.T. Rutgers, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
  • ,
  • Hester S.A. Oldenburg, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
  • ,
  • Jelle Wesseling, M.D., Ph.D.

      Affiliations

    • Department of Pathology, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
  • ,
  • Sabine C. Linn, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
  • ,
  • Nicola S. Russell, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
  • ,
  • Marie-Jeanne T.F.D. Vrancken Peeters, M.D., Ph.D

      Affiliations

    • Department of Surgery, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Received 18 January 2008; received in revised form 19 May 2008 published online 19 December 2008.

Abstract 

Background

Recently, lower axillary lymph node retrieval after neoadjuvant chemotherapy was reported. We did not have this experience, and retrospectively analyzed our axillary lymph node dissections (ALNDs).

Methods

One hundred ninety-one patients who had ALND after neoadjuvant chemotherapy were compared with 192 patients with primary ALND after a positive sentinel node biopsy.

Results

There were no differences in the mean number of nodes retrieved between the neoadjuvant group and the primary surgery group: 16.3 (range 4–38) and 15.8 (range 6–33), respectively (P = .4); or in the retrieval of fewer than 10 lymph nodes: 13/191 (7%) and 11/192 (6%) (P = .7). The number of cases with retrieval of more than 20 lymph nodes was higher in the neoadjuvant group: 42/191 (22%) versus 26/192 (13%) (P = .03). In the neoadjuvant group, 150/191 (79%) patients had residual lymph node metastasis after neoadjuvant chemotherapy.

Conclusion

Our results show the feasibility and need to remove enough lymph nodes to provide precise prognostic information and adequate local control.

Keywords: Breast cancer, Neoadjuvant chemotherapy, Axillary lymph nodes

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9610(08)00555-2

doi:10.1016/j.amjsurg.2008.05.006

The American Journal of Surgery
Volume 198, Issue 1 , Pages 46-50, July 2009